Akebia Therapeutics Inc AKBA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $0.53
- Day Range
- $0.49–0.55
- 52-Week Range
- $0.36–1.89
- Bid/Ask
- $0.54 / $0.55
- Shares Outstanding
- 277.66M
- Market Cap
- $150.44M
- Volume/Avg
- 5M / 8M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.74
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 194
- Website
- https://www.akebia.com
Valuation
Metric | AKBA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.38 |
Price/Sales | 0.74 |
Price/Cash Flow | 27.07 |
Price/Earnings
AKBA
Financial Strength
Metric | AKBA |
|---|---|
Quick Ratio | 1.21 |
Current Ratio | 1.36 |
Interest Coverage | −1.74 |
Quick Ratio
AKBA
Profitability
Metric | AKBA |
|---|---|
Return on Assets (Normalized) | −8.16% |
Return on Equity (Normalized) | −99.66% |
Return on Invested Capital (Normalized) | −21.04% |
Return on Assets
AKBA
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|wsgRHQS | LOCK|#xV$ | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|@@@gr<m | LOCK|#$dPg | $50B | |||
| Haleon PLC ADR HLN | LOCK|>kn$@# | LOCK|!# | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|@D^sT@x | LOCK|>? | $34B | |||
| Viatris Inc VTRS | LOCK|Q>>lB&& | LOCK|>y | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|!$^ | LOCK|<dW | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|>Dn!q%$ | LOCK|F!d | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|kCx%xD | LOCK|^WP | $4B | |||
| Perrigo Co PLC PRGO | LOCK|Fd?VC! | LOCK|fl! | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|&#sy@! | LOCK|b>jt! | $2B |
United States